0
0Recent research has established that the gut microbiota and its associated metabolic products are fundamental regulators of immune checkpoint blockade (ICB) efficacy in cancer treatment. These microorganisms influence therapeutic outcomes through various mechanisms, including antigenic cross-reactivity, the movement of microbes to lymph nodes, and the systemic circulation of metabolites like short-chain fatty acids. Furthermore, dietary habits significantly dictate these interactions, as high-fiber intake generally bolsters anti-tumor immunity while high-fat diets can lead to more varied or detrimental results. The composition of the microbiome also appears to play a critical role in the development of immune-related adverse events, such as inflammatory colitis. Despite these insights, the exact pathways through which the intestinal environment communicates with distal tumors remain a primary focus for future clinical advancement. Ultimately, harnessing this "gut-organ axis" offers a promising strategy to improve patient response rates and personalize cancer immunotherapy.
References:
Gladstone J, Sonnenberg G. Gut microbiota and metabolic control of immune checkpoint blockade in cancer. Cell Metabolism, 2026
